86 patents
Utility
Substituted indazoles as IRAK4 inhibitors
9 Jan 24
Ina Terstiege, Stefan Schiesser, Yafeng Xue, Hui-Fang Chang, Anna Ingrid Kristina Berggren
Filed: 1 Dec 21
Utility
N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
2 Jan 24
Jonas Brånalt, Maria Johansson, Anneli Nordqvist, Marianne Swanson
Filed: 12 Jun 23
Utility
Automated detection of safety signals for pharmacovigilance
19 Dec 23
An embodiment may involve obtaining a set of pre-defined features and a new document; extracting a subset of the pre-defined features from within new document; applying a natural language model to the new document, wherein the natural language model was pre-trained using scientific or medical literature and fine-tuned using a corpus of documents; applying a feature-based model to the subset of the pre-defined features extracted from the new document, wherein the feature-based model was trained with the pre-defined features and the respective labels of the documents; and applying an aggregation model to the classifications of the new document produced by the natural language model and the feature-based model, wherein the aggregation model was trained with prior classifications produced by the natural language model and the feature-based model so that the aggregation model produces a further classification of the new document representing its relevance to pharmacovigilance.
Alexandre Kiazand, Robert Hernandez, Antoni Wisniewski, Douglas Domalik, Tony Gill
Filed: 22 Jul 21
Utility
Method of treating fatty liver disease
12 Dec 23
The present disclosure provides methods of treating or preventing fatty liver disease and/or lowering cholesterol and LDL cholesterol levels in a subject.
Daniel Linden, Richard Lee, Stefano Romeo, Huynh-Hoa Bui
Filed: 21 Sep 21
Utility
Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
28 Nov 23
Methods for treating and/or preventing HFpEF and/or at least one disease, disorder, and/or condition associated therewith in patients by the use of dapagliflozin and compositions comprising the same are disclosed.
Anna Maria Langkilde
Filed: 18 Jul 19
Utility
Pharmaceutical composition
14 Nov 23
The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
Filed: 6 May 21
Utility
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
14 Nov 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jacqueline Anne Macritchie, Nicholas John Palmer
Filed: 10 Sep 22
Utility
Chemical compounds
24 Oct 23
Jeffrey Wallace Johannes, Sudhir Mahadeo Hande, Avipsa Ghosh, Xiaolan Zheng, Martin Packer, Sebastien Louis Degorce
Filed: 22 Jun 21
Utility
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
3 Oct 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
Filed: 9 Sep 22
Utility
Protein kinase B inhibitors
19 Sep 23
Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
Filed: 16 Dec 21
Utility
Amino-triazolopyridine compounds and their use in treating cancer
5 Sep 23
Maurice Raymond Verschoyle Finlay, Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting
Filed: 27 Aug 21
Utility
Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
22 Aug 23
The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
Peter Greasley, Christine Ahlström, Stanko Skrtic, Robert Menzies, Anne-Kristina Mercier, Mikael Sunnåker
Filed: 9 Jul 21
Utility
Therapeutic dendrimers
8 Aug 23
Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William Mccoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
Filed: 11 Nov 20
Utility
Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors
4 Jul 23
Johan Olof Broddefalk, Hans Fredrik Emtenâs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
Filed: 22 Apr 21
Utility
Biomarkers and methods of treating cancer
27 Jun 23
Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-α inhibitors or AKT inhibitors, are described.
Alvaro Avivar Valderas, Francisco Humberto Cruzalegui, Kevin Hudson, Robert Kenneth McEwen
Filed: 16 Sep 16
Utility
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
23 May 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
Filed: 9 Sep 22
Utility
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
23 May 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
Filed: 10 Sep 22
Utility
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
23 May 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan P O Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne MacRitchie, Nicholas John Palmer
Filed: 10 Sep 22
Utility
Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
23 May 23
Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
Filed: 10 Sep 22
Utility
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
28 Mar 23
Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
Filed: 1 Dec 20